Valneva's 15-min chart triggers Bollinger Bands narrowing, KDJ death cross, bearish Marubozu.

Valneva's 15-minute chart has exhibited a narrowing of Bollinger Bands, a KDJ Death Cross, and a Bearish Marubozu at 08/28/2025 13:45. This indicates a decrease in the magnitude of stock price fluctuations, a shift in momentum towards the downside, and a potential further decrease in stock price. Sellers currently control the market, and it is likely that the bearish momentum will continue.

Valneva SE (VALN) experienced a significant drop in its stock price following the United States Food and Drug Administration (FDA) suspension of the license for its Chikungunya vaccine, Ixchiq. The suspension, effective immediately, requires Valneva to halt the shipping and selling of Ixchiq in the U.S. [1]

The FDA cited four new reports of serious adverse events, including three in elderly individuals aged 70-82 years, and one death from encephalitis attributed to the vaccine. The suspension comes after the FDA lifted a previous pause on the vaccine's use for older adults on August 6. [2]

Analysts have expressed divergent opinions on the impact of this decision. Jefferies analyst Maury Raycroft lowered Valneva's price target to $14 from $18 while maintaining a 'Buy' rating. He noted that while Ixchiq is not a major revenue driver in the near term, the potential risk for ex-U.S. regulators to change their stance on Ixchiq licensure exists. [1]

H.C. Wainwright analyst Brandon Folkes, however, reiterated a 'Buy' rating on Valneva. He believes the stock selloff offers an attractive entry point for investors who are constructive on the potential positive readout for VLA15, the company’s investigational Lyme disease vaccine, later this year. [1]

The stock's recent performance has been marked by significant fluctuations. On August 28, 2025, Valneva's 15-minute chart exhibited a narrowing of Bollinger Bands, a KDJ Death Cross, and a Bearish Marubozu at 13:45. These technical indicators suggest a decrease in the magnitude of stock price fluctuations, a shift in momentum towards the downside, and a potential further decrease in stock price. Sellers currently control the market, indicating a likely continuation of bearish momentum. [3]

Valneva has not revised its revenue guidance for 2025 despite the FDA suspension. The company is evaluating the financial impact of the withdrawal of Ixchiq’s license in the U.S. In the first half of 2025, Ixchiq contributed €7.5 million ($8.74 million) to the company’s €91 million total product sales. [1]

References:
[1] https://stocktwits.com/news-articles/markets/equity/valneva-stock-tumbles-after-us-fda-suspension-of-ixchiq-license/chssvsiRdSe
[2] https://www.fiercepharma.com/pharma/fda-does-180-suspending-use-valnevas-chikungunya-vaccine
[3] https://www.investing.com/news/analyst-ratings/jefferies-lowers-valneva-stock-price-target-to-14-on-fda-suspension-93CH-4209311